全文获取类型
收费全文 | 1881篇 |
免费 | 119篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 8篇 |
儿科学 | 35篇 |
妇产科学 | 16篇 |
基础医学 | 355篇 |
口腔科学 | 14篇 |
临床医学 | 130篇 |
内科学 | 354篇 |
皮肤病学 | 306篇 |
神经病学 | 151篇 |
特种医学 | 45篇 |
外科学 | 145篇 |
综合类 | 14篇 |
一般理论 | 2篇 |
预防医学 | 62篇 |
眼科学 | 9篇 |
药学 | 125篇 |
中国医学 | 2篇 |
肿瘤学 | 231篇 |
出版年
2022年 | 11篇 |
2021年 | 14篇 |
2019年 | 12篇 |
2018年 | 15篇 |
2017年 | 21篇 |
2016年 | 23篇 |
2015年 | 33篇 |
2014年 | 32篇 |
2013年 | 52篇 |
2012年 | 82篇 |
2011年 | 81篇 |
2010年 | 43篇 |
2009年 | 42篇 |
2008年 | 87篇 |
2007年 | 84篇 |
2006年 | 79篇 |
2005年 | 97篇 |
2004年 | 115篇 |
2003年 | 103篇 |
2002年 | 100篇 |
2001年 | 72篇 |
2000年 | 62篇 |
1999年 | 62篇 |
1998年 | 28篇 |
1997年 | 36篇 |
1996年 | 28篇 |
1995年 | 23篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 51篇 |
1991年 | 46篇 |
1990年 | 35篇 |
1989年 | 23篇 |
1988年 | 28篇 |
1987年 | 26篇 |
1986年 | 22篇 |
1985年 | 17篇 |
1984年 | 29篇 |
1983年 | 10篇 |
1982年 | 9篇 |
1979年 | 19篇 |
1978年 | 11篇 |
1976年 | 10篇 |
1975年 | 11篇 |
1974年 | 20篇 |
1973年 | 20篇 |
1972年 | 13篇 |
1971年 | 13篇 |
1970年 | 16篇 |
1969年 | 9篇 |
排序方式: 共有2004条查询结果,搜索用时 75 毫秒
1.
2.
3.
Dabis Maleate (1,4-bis(2'-chloroethyl)-1,4-diazabicyclo[2.2.1] Heptane dihydrogen dimaleate) (NSC 262666) is an alkylating quaternary nitrogen compound. In a previous phase I study using a once-every-3-weeks administration the dose-limiting toxicity was neurotoxicity and the recommended dose for phase II studies was 750 mg/m2 iv every 3 weeks. In vitro studies suggested a higher activity after more frequent administration, and in vivo studies a better therapeutic index with prolonged infusion. We studied 11 patients with solid tumors. Dose levels tested ranged from 250-750 mg/m2, either as a day 1-3 regimen or weekly, the latter as bolus administration or as prolonged infusion. The dose-limiting toxicity was neurotoxicity consisting of paresthesias and ataxia. Nausea and vomiting were moderate. No other major toxicity was observed. The dose recommended for phase II studies is 500 mg/m2/week as a 6-hour iv infusion for 6 weeks, followed by a 3-week rest period. 相似文献
4.
A. S. Planting M. E. van der Burg M. de Boer-Dennert G. Stoter J. Verweij 《British journal of cancer》1993,68(4):789-792
Twenty-five patients with advanced solid tumours were entered in a phase I/II study of six, weekly cycles of cisplatin. Nineteen patients were chemonaive and six were previously treated. The starting dose was 50 mg m-2 week-1. This dose could be escalated without major toxicity to 70 mg m-2 week-1. At a dose of 80 mg m-2 myelosuppression grade 3 occurred as well as grade 1 nephro- and neurotoxicity. The maximum tolerated dose was 85 mg m-2 with dose limiting thrombocytopenia. Hypertonic saline was effective in preventing nephrotoxicity. Ondansetron was a very effective antiemetic in the first weeks of treatment but its efficacy waned later on. Responses were observed in head and neck cancer, melanoma and mesothelioma. At the dose level of 80 mg m-2 the optimal dose intensity was reached. This schedule will be tested further in phase II studies. 相似文献
5.
Neuron-specific enolase (NSE), a glycolytic enzyme enolase found in brain, was examined in the cerebrospinal fluid and serum of 30 patients with presumptive Alzheimer's disease (AD) and of 13 healthy controls and evaluated as a measure of neuronal functional activity associated with AD. The cerebrospinal fluid NSE levels of patients with AD were significantly reduced and serum NSE levels were significantly increased from controls. Cerebrospinal fluid NSE levels may be representative of central nervous system cell loss or a decrease in neuronal functional activity associated with AD. 相似文献
6.
H M Blottière A Menoret C Burg J Y Douillard J Le Pendu 《International journal of cancer. Journal international du cancer》1992,50(2):315-320
Sera from BDIX rats inoculated with 2 tumor clones derived from a single syngeneic colon carcinoma were assayed by Western blotting for the presence of antibodies against the grafted tumor. The PROb clone is progressive and produces metastases. We observed that rats bearing this tumor developed antibodies against an unglycosylated water-soluble protein of 105 kDa. The magnitude of this humoral response, as assessed by the intensity of the signal on immunoblots, was inversely correlated with survival of the rats. Furthermore, rats inoculated with the REGb clone, which is immunologically rejected, never developed detectable antibodies against the tumor. Antisera from rats injected with PROb tumor detected p105 antigen in cellular extracts from the REGb clone and from a series of rat and human cell lines. This protein was also detected in variable amounts in some normal adult and fetal tissues. Treatment of PROb or REGb cells by either interferon-gamma or heat shock did not significantly alter the expression of the p105 auto-antigen. 相似文献
7.
Nina Rieckmann William Gerin Ian M Kronish Matthew M Burg William F Chaplin Grace Kong Fran?ois Lespérance Karina W Davidson 《Journal of the American College of Cardiology》2006,48(11):2218-2222
OBJECTIVES: We tested whether improvements in depressive symptoms precede improved adherence to aspirin in patients with acute coronary syndromes (ACS). BACKGROUND: Depression is associated with medication nonadherence in patients with ACS, but it is unclear whether changes in depression impact on adherence. METHODS: Electronic medication monitoring was used to measure adherence to aspirin during a 3-month period in a consecutive cohort of 172 patients (25 to 85 years) recruited within 1 week of hospitalization for ACS. Depressive symptom severity was assessed using the Beck Depression Inventory (BDI) during hospitalization and at 1 and 3 months after hospitalization. Adherence was defined as the percentage of days aspirin was taken as prescribed. RESULTS: Depression severity in hospital was associated with nonadherence in a gradient fashion: 15% of non-depressed patients (BDI score 0 to 4), 29% of mildly depressed patients (BDI score 10 to 16), and 37% of patients with moderately-to-severely depressive symptoms (BDI score >16) took aspirin less than 80% of the time (p = 0.03). A cross-lagged path analytic model revealed that improvements in depressive symptoms in the first month after the ACS were associated with improvements in adherence rates in the subsequent 2 months (standardized direct effect -0.32, p = 0.016). CONCLUSIONS: Diagnosis and treatment of depressive symptoms may improve medication adherence in patients after ACS. 相似文献
8.
9.
We evaluated the effect of different manipulations on the performance of a standardized counting task in 7 patients with idiopathic jaw-opening dystonia. Patients used a small stick as sensory stimulus. Following conditions were examined: stick placed between teeth and cheek (CHEEK), biting on stick (TEETH), voluntary jaw occlusion without stick (OCCLUSION). Articulation was rated by patients and experimenters and surface electromyographic activity (EMG) was recorded. Patient-rating (CHEEK - 36.6%, TEETH - 48.1%) and EMG (-18.1%; -17.3%) were significantly improved for conditions using the stick, whereas experimenter-rating showed a trend for TEETH (-16.2%). Although jaw occlusion during speaking deteriorates articulation in healthy subjects, there was no further deterioration in patients and EMG was even significantly reduced (-18.6%). Comparable results were obtained in 1 patient using a special dental device. We conclude that sensory tricks significantly improve subjective and objective parameters. Besides tactile stimulation, altered proprioceptive feedback and antagonist activation may modulate hyperactive dystonic networks. 相似文献
10.